GMP Manufacture Deal With Cobra

22/01/2009

GB00B39J5N63

                             Scancell Holdings Plc                             

                    (`Scancell Holdings' or the `Company')                     

               GMP manufacture deal with Cobra Biomanufacturing                

Scancell Holdings Plc, the parent company of Scancell Limited (`Scancell'), the
developer of therapeutic cancer vaccines based on its patented ImmunoBodyâ„¢
platform, is pleased to announce that it has signed a deal with Cobra
Biomanufacturing Plc (`Cobra Biomanufacturing') for Good Manufacturing Practice
(`GMP') manufacture of its SCIB1 DNA vaccine. Scancell plan to commence
clinical trials of SCIB1 in the UK in 1Q2010.

Scancell is developing SCIB1, a DNA vaccine for the potential treatment of
late-stage melanoma cancer patients. There are 8000 new cases of melanoma every
year in the UK with 1800 deaths per year. Early stage melanoma is often cured
by surgery but advanced disease has a very poor prognosis with late stage
(stage IV) disease having a median survival of approximately 6 months. SCIB1
was developed using Scancell's ImmunoBodyâ„¢ technology and is engineered to
express the TRP-2 and gp100 cytotoxic T-cell epitopes from tumour antigens. In
animal models, SCIB1 prevented the development of lung metastases and
significantly inhibited the growth of established tumours.

Cobra Biomanufacturing is an AIM-listed contract manufacturer of
biopharmaceuticals that is compliant with cGMP standards worldwide.

David Evans, chairman of Scancell, commented:

"We are delighted to sign a deal with Cobra Biomanufacturing to manufacture our
SCIB1 DNA vaccine. That we are commencing GMP manufacture of SCIB1 on schedule
is testament to the progress the Company continues to achieve."

Simon Saxby, Chief Executive of Cobra Biomanufacturing said:

"We are very pleased to be have been selected by Scancell as a result of
Cobra's abilities and reputation as a leading cGMP compliant manufacturer of
DNA. This agreement also underscores Cobra's long term commitment to the
manufacture of therapeutic vaccines."

The Directors of the issuer accept responsibility for this announcement.

                                    -ENDS-                                     

For Further Information:

Professor Lindy Durrant         Scancell Holdings Plc    + 44 207 245 1100   
                                                                             
Adam Reynolds/Vikki Krause      Hansard Group            + 44 7515 922906    
                                                                             
Duncan Vasey/Barry Hocken       St. Helen's Capital Plc  + 44 207 628 5582